Catalent (CTLT) to Acquire MaSTherCell Global for $315 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
Catalent, Inc. Reports Second Quarter Fiscal 2020 Results
February 3, 2020 7:30 AM ESTQ2'20 revenue of $721.4 million increased 16% as-reported, or 17% in constant currency, from Q2'19. Accelerated growth in the Biologics segment. Solid organic growth in the Softgel and Oral Technologies and Clinical Supply Services segments more than offset decline in the Oral and Specialty Delivery segment. Announcing further expansion of Biologics footprint with agreement to acquire MaSTherCell, a leading cell therapy development and manufacturing partner with facilities in Brussels, Belgium and Houston, Texas. Raising FY'20 financial guidance range, primarily due to continued growth of recently acquired... More
